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Purpose: Retinitis pigmentosa (RP), a retinal neurodegenerative disorder characterized by apoptosis of photoreceptor
cells, is caused by mutations in many different genes. We analyzed the RP gene ceramide kinase-like (CERKL) to determine
CERKL function and contribution to pathogenesis.
Methods: RT–PCR was performed to characterize CERKL expression in many human adult and fetal tissues, including
retina. We analyzed the protein subcellular localization by confocal microscopy and further verified it by sucrose gradients.
We  performed  lipid  kinase  activity  assays.  And  finally,  we  studied  the  effects  on  cell  apoptosis  after  CERKL
overexpression in transiently transfected cultured cells by propidium iodide staining and poly-(ADP-ribose)-polymerase
(PARP) caspase-dependent cleavage.
Results: CERKL transcripts underwent alternative splicing. In the human retina, four different CERKL isoforms of 532,
558, 419, and 463 amino acids were expressed. CERKL proteins were mainly localized in the endoplasmic reticulum and
Golgi compartments, but they also shifted localization to nuclei and nucleoli. We also found that CERKL prevented cells
from entering apoptosis induced by oxidative-stress conditions.
Conclusions: CERKL remains a unique orphan lipid kinase in that no candidate substrate has been identified after intense
research. The dynamic localization of CERKL suggests multiple sites of action. Remarkably, CERKL (but not the RP
R257X mutant) exerts a protective role in cells against oxidative stress, consistent with RP mutations impairing the normal
protein function in photoreceptors and thus tilting the balance toward apoptosis. These results provide valuable insights
into the molecular mechanisms causing retinal degeneration.
Retinitis  pigmentosa  (RP)  is  an  inherited  retinal
neurodegenerative disorder characterized by the progressive
attrition of photoreceptor cells through apoptosis. Although
mutations in many different genes have the same phenotypic
outcome,  there  is  not  much  information  gathered  on  the
biochemical processes linking the genotype to the eventual
photoreceptor death. In the course of our search for new genes
causing autosomal recessive RP in several Spanish families,
we identified a previously unannotated gene, ceramide-kinase
like (CERKL) [1,2]. Mutations in CERKL are responsible for
a phenotypically distinct RP [2,3], with characteristic macular
and peripheral lesions. The name of the gene stems from the
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diacylglycerol  kinase  domain–which  shares  homology  to
ceramide kinases–of the encoded protein.
Ceramide  is  a  chore  sphingolipid  (SL),  being  the
precursor of other bioactive and complex SLs and one of the
initial key players in stress-induced apoptosis [4]. SLs are now
considered  lipid  second  messengers  that  behave  as  finely
tuned sensors of cell status [4,5]. Accordingly, the enzymes
involved in SL metabolism, and among them CERKL, are
rheostats that integrate multiple stress stimuli [6]. Mutations
in these genes cause multiple and complex phenotypic effects,
including severe neurodegenerative disorders [7]. A variety
of extracellular and intracellular stimuli, including cytokines,
cytotoxic agents, and stress signals, cause the accumulation
of  ceramide  via  sphingomyelin  hydrolysis  or  de  novo
synthesis. To avoid entering apoptosis, cells counteract this
ceramide increase by activating enzymatic pathways involved
in ceramide clearance. In this context, the phosphorylation of
ceramide by ceramide kinase exerts a protective role against
apoptosis. Ceramide can be produced in different subcellular
membranous compartments, adding to the complexity and the
homeostasis  of  the  whole  system  [6,8].  Therefore,  the
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168identification of CERKL as an RP gene provided a missing
link  between  alterations  in  SL  metabolism  to  inheritable
retinal disorders and suggested a new avenue for elucidating
the ethiopathological mechanisms.
Here  we  report  that  CERKL  undergoes  alternatively
splicing events, which affect the exons encoding the lipid
kinase domain. Four protein isoforms are generated, although
only 2 of them contain the complete diacylglycerol (DAG)
kinase domain. Here we present a detailed characterization of
the expression of these 4 alternatively spliced isoforms in
different human tissues, and demonstrate that these 4 variants
are only present in the retina. The 4 proteins show a similar
subcellular localization pattern, and are mainly located in the
ER and Golgi compartments. Although CERKL substrates
remains elusive under standard experimental conditions, we
show that overexpression of CERKL isoforms protects cells
from apoptosis induced by oxidative stress.
METHODS
Cloning of CERKL splicing variants in the human retina:
Specific primers flanking exons 2 and 13 (Table 1) were used
to clone CERKL alternative splicing variants by PCR from
Marathon-Ready™ human retina cDNA (BD Biosciences,
Franklin Lakes, NJ) under the following conditions: 94 °C for
30 s, 58 °C for 30 s, and 72 °C for 2 min for 35 cycles. The
primer  CERKL_E2_F  annealed  to  exon  2  while  the
CERKL_E13_R primer annealed to exon 13 and introduced
a BamHI site to facilitate subsequent subcloning. The 50 μl
reaction mixture contained 10 μM of each primer, 2 μM of
dNTPs, 1.5 mM MgCl2 and 1 U of Pfu Turbo polymerase
(Stratagene, La Jolla, CA). The PCR bands detected after
electrophoresis on a 1.5% agarose gel were cloned into the
EcoRV site of pBluescriptII KS and verified by sequencing.
The  full-length  cDNAs  of  these  CERKL  isoforms  were
reconstituted by digesting the partial clones with EcoRI and
BamHI and subcloning the corresponding fragments into a
pBluescriptII KS vector that already contained the 5′ end of
CERKL (the complete exon 1 and the stretch of exon 2 before
the EcoRI site, obtained from the IMAGE clone 3870103).
RT–PCR analysis of the presence of CERKL splicing variants
in  human  tissues:  The  splicing  pattern  of  CERKL  was
analyzed in human retina cDNA and a panel of first-strand
cDNAs from several human adult and fetal tissues, using
specifically  designed  pairs  of  primers  to  amplify  and
distinguish each isoform (Table 1), as follows: 1) to detect
splicing variants CERKLa and CERKLb (RT_CERKLab_F
and  RT_CERKLab_R);  2)  to  amplify  splicing  variant
CERKLc  (RT_CERKLc_F  and  RT_CERKLcd_R);  3)  to
detect  splicing  variant  CERKLd  (RT_CERKLd_F  and
RT_CERKLcd_R).  Two-step  PCR  conditions  were  as
follows: 35 cycles of 94 °C for 30 s and 58 °C for 30 s. The
25 μl reaction mixture contained 10 μM of each primer, 2 μM
of dNTPs, 1.5 mM MgCl2 and 1 U Taq polymerase (Promega,
Madison, WI). The concentration of the Marathon-Ready™
human retina cDNA and first-strand cDNAs from the tissue
panel (BD Biosciences) in the reactions were 0.01 ng/μl and
0.1 ng/μl, respectively.
Overexpression  of  CERKL  isoforms  in  cultured  cells  and
preparation  of  protein  cell  lysates:  Expression  vectors
containing  the  full-length  open  reading  frame  of  the  four
CERKL isoforms were assembled by PCR amplification of
each variant using the CERKL_E2_F primer, which anneals
upstream  of  the  EcoRI  site  in  exon  2  and  the
CERKL_E13_HA_R primer, which anneals in exon 13 (Table
1). Primer CERKL_E13_HA_R also encoded a C-terminal
hemagglutinin (HA) epitope tag and included an EcoRV site
for subsequent cloning. The PCR products were digested with
EcoRI and EcoRV and cloned into a pcDNA3 (Invitrogen Life
Technologies, Carlsbad, CA) that contained exons 1 and 2 of
CERKL (previously cloned between HindIII and EcoRI sites).
The integrity of all constructs was verified by sequencing. To
generate  the  truncated  RP  mutant  protein  (R257X),  site-
directed  mutagenesis  was  performed  on  the  2  constructs
containing  the  isoforms  CERKLa  and  CERKLb
TABLE 1. CERKL AMPLIFICATION PRIMERS FOR THE CONSTRUCTION OF EXPRESSION VECTORS AND THE RT–PCR ANALYSES.
Forward primers (5′-3′)
CERKL_E2_F CTGTTAAACAGCAGAGAAGTGGTAC
RT_CERKLab_F GTAACAATAATGGAATATGAAGGG
RT_CERKLc_F CAGTTCAAGAAAATATTGGCAGGATC
RT_CERKLd_F GGAATAAAAACTGATGTAACAAGATC
mutCERKL_Fc TGGGATGGAAACAGACTGAATCCTGACTCCTGTC
Reverse primers (5′-3′)
CERKL_E13_Ra ATGGATCCTTACTTTGGAATCATTTCTTCCATG
RT_CERKLab_R ATCCTGCTGGTATTAAGCCAAG
RT_CERKLcd_R CCTTAACAACAGCAAAATCTCTCCG
CERKL_E13_HA_Ra,b CGGATATCAAGCGTAATCTGGAACATCGTATGGGTACTTTGGAATCATTTCTTCC
mutCERKL_Rc GACAGGAGTCAGGATTCAGTCTGTTTCCATCCCA
aCERKL_E13_R  and  CERKL_E13_HA_R  introduce  a  restriction  site  (indicated  in  italics)  for  subsequent  cloning.
bCERKL_E13_HA_R contains the coding sequence of the HA epitope (underlined).  cThe truncated R257X CERKL proteins
were obtained by site-directed mutagenesis using the primers mutCERKL_F and mutCERKL_R, which introduce the 847C>T
change (in bold and underlined).
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169(encompassing the lipid kinase domain). The 847C>T change
was introduced with the mutCERKL_F and mutCERKL_R
primers (Table 1). In these constructs, the HA epitope was
added to the N-terminus of the protein for immunodetection.
Human embryonic kidney (HEK293T) or African green
monkey kidney (COS-7) cells were seeded at 3×106 cells/dish
in 10 cm cell culture dishes 1 day before transfection. Cells
were tranfected with 24 µg/dish using either the pcDNA3
vector alone or each pcDNA3–CERKL construct and 60 µl/
dish of Lipofectamine™2000 (Invitrogen Life Technologies),
following the manufacturer’s instructions. After 2 days, the
cells were harvested and lysed by sonication in lysis buffer
[20 mM MOPS pH 7.2, 2 mM EGTA, 1 mM dithiothreitol,
10%  glycerol,  and  complete™  protease  inhibitor  (Roche
Diagnostics, Indianapolis, IN)], as described elsewhere [9].
In vitro and in vivo kinase activity assays: DAG and ceramide
kinase  activities  were  assayed  in  vitro  as  described  [10].
Briefly, the source of the enzymatic activity were protein
lysates from either HEK293T or COS-7 cells transfected with
each CERKL isoform (250 µg total protein), the empty vector
or  a  CERK-expressing  construct  (negative  and  positive
control, respectively) obtained by sonication in 20 mM MOPS
pH 7.0, 2 mM EGTA, 1 mM DTT, 10% glycerol plus protease
inhibitors.  The  source  of  lipids  were  either:  a)  micelles
obtained from commercial sphingolipids, which contained
880 µM lipids (ceramide and sphingosine, both from bovine
brain  sphingomyelin,  or  1,2-dioleoyl-sn-glycerol,  Sigma-
Aldrich,  St.  Louis,  MO),  1  mM  cardiolipin,  1.5%  β-
octylglucoside, 0.2 mM diethylenetriamine-pentaacetic acid
(DETAPAC); b) lipid micelles, obtained by sonication of
50  μg  of  lipids  extracted  from  cultured  661W  murine
photoreceptor-derived cells in 1 mM DETAPAC, 7.5% β-
octylglucoside; or c) total 661W cell lysates that were heat-
inactivated  at  65  °C  for  20  min  to  abrogate  endogenous
enzymatic activities. Reactions were performed at 100 µl final
volume containing 20 mM MOPS pH 7.2, 50 mM NaCl, 1 mM
dithiothreitol,  2  mM  EGTA,  and  3  mM  CaCl2,  with  the
corresponding  lipid  and  protein  sources.  Reactions  were
started by adding MgCl2 at 0.5 mM final concentration plus
γ-32P-ATP (2–5 µCi/reaction), incubated at 30 °C for 30 min,
60 min, or overnight, and stopped with 250 µl of chloroform,
250 µl of methanol and 125 µl HCl 2.4 M. After vortexing,
the phases were separated by centrifugation, and the organic
phase removed and vacuum-dried. Lipids were resuspended
in 25 µl chloroform:methanol (95:5, v/v), spotted onto silica
gel plates and separated by thin-layer chromatography (TLC).
For the enzymatic assays in vivo, we seeded 1.5×106 661W
cells on 10 cm diameter plates and transfected using either the
two pEGP-CERKL long isoforms (a and b) or the pEGFP
empty-vector  (negative  control).  Transfected  cells  were
enriched  by  using  Fluorescence  Activated  Cell  Sorting
(FACS) to select green fluorescent protein (GFP) positive
cells. These cells were reseeded on smaller plates, and 4 μl of
radioactive  32P-orthophosphate  was  added  to  the  medium.
Cells were collected after 4 h, and lysed directly in a solution
of chloroform:methanol:chlorhydric acid (100:100:1). After
vigorous  vortexing,  cellular  debris  was  sedimented  by
centrifugation in a microfuge (100x g) and the liquid phase
was  vacuum-dried  on  completion.  The  lipid  pellet  was
resuspended in a solution of 1:1 chloroform:methanol and
loaded onto silica gel 60 TLC plates (Merck, Whitehouse
Station, NJ). All TLCs (assays in vivo and in vitro) were run
in  chloroform:acetone:methanol:acetic  acid:water
(10:4:3:2:1,  v/v).  Radiolabeled  lipids  were  visualized  by
autoradiography.
Purification of recombinant proteins: To express the four
CERKL isoforms as glutathione-S-transferase (GST) fusion
proteins, we subcloned each variant in-frame into pGEX-4T-1
(Amersham Biosciences, Chalfont St. Giles, UK), between
the XhoI and NotI sites. The constructs were transformed into
BL21 Codon Plus E.coli cells (Stratagene) to avoid premature
protein truncation due to the strongly biased codon usage of
the  CERKL  human  gene.  Recombinant  proteins  were
produced in 500 ml cultures induced by the addition of 0.5 mM
Isopropyl-β-D-thiogalactopyranoside (IPTG). Purified GST-
recombinant proteins were obtained after elution with reduced
glutathione of the protein bound to the glutathione-sepharose
bead  batch,  following  the  manufacturer’s  instructions
(Amersham Biosciences).
Lipid-protein overlay assay: Binding of CERKL isoforms to
sphingolipids was assessed using SphingoStrips™ and PIP
Strips™ (Echelon Biosciences, Salt Lake City, UT), which
consist of several nitrocellulose-immobilized sphingolipids
and  phosphoinositides  (100  pmol/spot)  respectively.  The
membranes were equilibrated for 5 min in 10 mM Tris-HCl
pH 8.0, 150 mM NaCl, and 0.1% v/v Tween-20 (TBST). They
were then blocked with 3% BSA in TBST (blocking solution)
for 1 h at room temperature. Subsequently, the membrane was
then  incubated  overnight  at  4  °C  in  blocking  solution
containing 0.5 µg/ml of the GST-fusion protein on a rocking
platform. The membranes were washed twice for 15 min in
TBST with gentle agitation, and then incubated for 1 h with
1:1,000  anti-GST  monoclonal  antibody  (Santa  Cruz
Biotechnology, Santa Cruz, CA). After washing as before,
membranes were incubated for 1 h with 1:3,000 horseradish
peroxidase-conjugated  anti-mouse  IgG  antibody  (Sigma).
Finally, the membranes were washed 6 times in an hour in
TBST, and developed with the ECL western blotting detection
system (Amersham Biosciences).
Transfection,  immunolocalization  and  confocal  laser
microscopy: COS-7 cells were grown in Dubecco’s Modified
Eagle Medium (DMEM) containing 10% fetal bovine serum,
4 mM L-glutamine, 100 U/ml of penicillin, and 100 µg/ml
streptomycin  (Invitrogen  Life  Technologies).  Cells  were
grown on coverslips in 12 well plates. Transient transfections
were performed using Lipofectamine™2000 (Invitrogen Life
Technologies)  according  to  the  manufacturer’s  protocol.
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170Next, 24 h or 48 h post-transfection cells were rinsed with PBS
1X (137 mM NaCl, 2.7 mM KCl, 1.5 mM KH2PO4, 8 mM
Na2HPO4, pH 7.4) and fixed in 3% paraformaldehyde and 2%
sucrose in 0.1 M phosphate buffer at 4 °C for 30 min. Cells
were  then  washed  and  permeabilized  for  10  min  with  a
solution that contained 0.1% Triton X-100, 20 mM glycine,
and 10 mM PBS. After permeabilization, cells were rinsed and
blocked in a solution composed of 1% BSA, 20 mM glycine,
and 10 mM PBS. Then, cells were incubated with 1:250 anti-
HA polyclonal antibody and either specific 1:25 anti-calnexin,
1:250  anti-GM130,  or  1:1,000  anti-EEA1  monoclonal
primary antibodies (all from BD Biosciences) at 37 °C for 1
h. Mitochondria were labeled by adding reduced MitoTracker
Orange  (Molecular  Probes,  Invitrogen  Life  Technologies,
Carlsbad,  CA)  to  the  cell  culture  medium  at  a  final
concentration  of  500  nM  for  45  min  before  the  fixation
procedure  and  subsequent  immunocytochemistry.  Upon
washing, cells were incubated with 1:300 AlexaFluor 488-
conjugated anti-rabbit and 1:300 AlexaFluor 546-conjugated
anti-mouse (Molecular Probes) secondary antibodies. When
required,  slides  were  counter-stained  with  1:200  DAPI
(Sigma) nuclear blue dye in PBS for 15 min. All preparations
were  mounted  in  Vectashield  medium  for  fluorescence
(Vector  Laboratories,  Burlingame,  CA)  and  analyzed  by
confocal laser scanning microscopy with Olympus Fluoview
500 (Olympus, Tokyo, Japan) and Leica TSC NT and TSC
SPII (Leica, Wetzlar, Germany) laser scanning microscopes.
In silico predictions for CERKL subcellular localization were
performed using PSORT, ProSLP v2.0, ESLPred, and SubLoc
v1.0.
Subcellular fractionation by sucrose gradient:  HeLa cells
(human cervical cancer derived cell line ATCC CCL-2) were
seeded (1.5×106 cells/dish) in 10 cm plates and transfected
with the CERKLa isoform tagged with the HA epitope. At 48
h post-transfection, cells were washed twice with 1X PBS, and
then incubated 20 min at 4 °C in a solution that contained
10 mM Tris HCl, pH 7.4, 3% sucrose w/v, and 1% protease
inhibitors (Roche). After this incubation, the concentration of
sucrose was increased up to 0.25 M, and cells were broken by
15 strokes in an iced-chilled Dounce homogenizer. Cellular
debris,  nuclei,  and  unbroken  cells  were  separated  by
centrifugation  at  1,300x  g  for  5  min  at  4  °C,  and  the
supernatant was further centrifuged overnight at 100,000x g
at 4 °C. The pellet containing cell organelles was resuspended
in 1.5 M sucrose and laid at the bottom of a 1.8 ml swing-out
(Beckman, Fullerton, CA) centrifuge tube. Subsequent layers
of equal volumes of 1.15, 0.9, 0.6, and 0.25 M sucrose were
added, and the final sucrose gradient was centrifuged for 2 h
at 100,000x g at 4 °C. Next, 11 fractions of approximately
150 μl were collected from bottom to top. Samples were
loaded  onto  10%  polyacrylamide  SDS–PAGE  gels,
transferred  to  0.45  µm  polyvinylidene  fluoride  PDVP
membranes  (Immobilon-P,  Millipore,  Billerica,  MA)  and
underwent  immunodetection  with  the  corresponding
antibodies.
Immunodetection: After blocking membranes for 1 h in 10%
nonfat milk in phosphate buffered saline, 0.1% Tween-20
(MTP), membranes were incubated overnight at 4 °C or 1 h
at room temperature, separately, with any of the following
primary antibodies, all diluted at 1:1000, anti-GM130 (BD
Biosciences), anti-PDI (BD Biosciences), anti human TGN38
(Santa  Cruz  Biotechnology,  Inc.)  or  anti-HA  (Covance,
Princetown, NJ). After extensive washes in MTP, membranes
were incubated for 1 h with 1:3,000 of the corresponding
peroxidase-conjugated secondary antibody (Sigma), and the
bands  were  visualized  using  the  ECL  western  blotting
detection system (Amersham Biosciences).
Propidium iodide staining assay: COS-7 cells were grown on
coverslips  in  24  well  plates.  Transient  transfections  were
performed on the following: the constructs encoding each of
the four isoforms (pcDNA3-CERKL), the truncated variant
(pcDNA3-R257X), empty pcDNA3.1 (negative control), or
pcDNA6.2-DEST-CERK  (provided  by  F.  Bornancin,
Novartis). At 44 h post-transfection, cells were treated with
200 µM H2O2 (Fluka, Sigma-Aldrich, St. Louis, MO) and 3 h
later propidium iodide was added at a final concentration of
7 µg/ml. After 1 h, cells were rinsed twice with PBS and fixed
in 3% paraformaldehyde and 2% sucrose in 0.1 M phosphate
buffer at 4 °C for 30 min. They were then washed 2 times in
0.1  M  PBS  and  mounted  in  Vectashield  medium  (Vector
Laboratories). Several fields were analyzed under the visible
and green light channels in a fluorescence microscope (Leica
DM IL) coupled to a Leica DFC camera (Leica, Wetzlar,
Germmany).  A  minimum  of  500  cells  were  counted  and
compared to detect pignotic nuclei in the total cell count.
Three  independent  replicates  were  performed  for  each
construct.
Analysis of PARP cleavage-dependent apoptosis: HeLa cells
were seeded in 24 well plates and transfected with either
empty pcDNA3.1 (negative control) or pcDNA3-CERKLa
(containing  the  lipid  kinase  domain).  At  40  h  post-
transfection,  the  medium  was  replaced  by  fresh  solution
containing  one  of  the  following:  300  µM  H2O2,  400  µM
H2O2,  or  0.3  M  sodium  nitroprusside  (Fluka),  or  serum-
deprived medium. After 24 h, cells were rinsed with PBS,
harvested,  and  lysed  directly  in  protein  electrophoresis
loading  buffer.  Samples  were  then  boiled  for  5  min  and
centrifuged to sediment cellular debris. Protein preparations
were  loaded  onto  7.5%  SDS–PAGE  gels.  Either  1:1,000
monoclonal  anti-PARP  (Invitrogen  Life  Technologies)  or
1:8,000  monoclonal  anti-tubulin  (Sigma)  were  used  as
primary  antibodies.  Anti-mouse  secondary  antibody  was
conjugated  to  1:3,000  horseradish  peroxidase.
Immunodetection  was  performed  using  chemiluminescent
ECL  reagents  (GE  Healthcare,  Waukesha,  WI),  and  the
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171intensity of each band was quantified using the Quantity-One
1-D Analysis Software (Bio-Rad, Hercules, CA).
RESULTS
CERKL transcripts are alternatively spliced in the human
retina: The initially characterized CERKL gene spanned 13
exons  in  chromosome  2q31.2–31.3  (Figure  1A).  While
attempting to clone the full-length CERKL on retina cDNA
using primers spanning the ATG (forward) and the STOP
(reverse) codons, we observed several faint bands, which were
indicative  of  alternatively  spliced  variants.  Therefore,  we
devised  a  two-step  strategy  of  RT–PCR  and  cloning  (see
Methods) to characterize the full-length isoforms based on the
structure of the gene. The RT–PCR analysis of human retina
mRNA using primers from exons 2 and 13 allowed us to
identify several spliced transcripts (Figure 1A) that would
result in several protein isoforms (Figure 1 B): 1) CERKLa,
which  corresponded  to  the  already  reported  variant  [2],
spanning 13 exons and encoding a 532 amino acid protein
(GenBank accession number AY357073); 2) CERKLb, a 14
exon isoform, which includes an additional exon (4b) between
exons 4 and 5 and encodes a 558 amino acid protein (accession
number AY690329); 3) CERKLc, a splicing variant devoid
of exons 3-4-4b-5, which encodes a 419 amino acid protein
(accession number AY690330); and 4) CERKLd, a splicing
variant that skips exons 4-4b-5 and encodes a 463 amino acid
protein (accession number AY690331). Two very faint bands
corresponded  to  not  in-frame  splicing  variants  (accession
numbers  AY690332  and  AY690333)  that  would  generate
prematurely  truncated  proteins.  These  were  considered
aberrant  transcripts,  and  given  the  mRNA  quality  control
regulation, if they were produced in cells, they would be most
probably cleared by the nonsense mediated decay mechanism.
The longest isoforms (CERKLa and CERKLb) contained
the  complete  DAG  domain  and  a  putative  N-terminal
pleckstrin homology (PH) region. In contrast, the short forms
(CERKLc and CERKLd) skipped most of the DAG kinase
domain, although the putative PH domain (encoded in exons
1 and 2) was preserved (Figure 1B).
Noticeably,  exons  4b  and  5,  which  are  alternatively
spliced, show the rare GC donor splice site instead of the more
common GT (marked by asterisks in Figure 1A). Both exons
and  the  GC  donor  site  sequences  are  conserved  in  the
chimpanzee genome. The mouse Cerkl gene, which shows
overall strong conservation in exon and intron structure, has
no equivalent for exon 4b, thus suggesting that there are only
3 CERKL isoforms in the mouse. Again, the donor site of exon
5 in rodents is GC.
CERKL  shows  a  complex  alternative  splicing  pattern  in
human tissues: As we had previously found that CERKL was
expressed in a variety of human adult and fetal tissues [2], we
searched for CERKL isoforms in tissues other than retina. To
this end, we used a panel of first strand cDNAs from several
human  tissues.  In  accordance  with  our  previous  data,  no
CERKL isoform was found in adult skeletal or heart muscle.
However, some of the four in-frame splicing variants were
detected in other adult and fetal tissues (Figure 2). cDNAs
encoding protein isoforms CERKLa and CERKLb (with an
intact DAG kinase domain) were present in adult liver and
pancreas, as well as in fetal brain, lung, and kidney. One or
both short isoforms (c and d) were detected in adult lung, adult
kidney, adult pancreas, fetal lung, and fetal liver. Notably,
Figure 1. CERKL isoform structure. A:
The diagram shows the genomic exon-
intron structure of the CERKL gene with
the  initiation  and  stop  codons.  The
position  of  the  nonsense  mutation
(R257X)  identified  in  RP  families  as
well as the splicing junctions resulting
in isoforms a, b, c, and d are indicated.
Asterisks  indicate  the  position  of  the
rare  GC-splicing  donor  sites.  B:  The
mature  CERKL  mRNA  isoforms,
indicating  the  relative  position  of  the
encoded DAG kinase and putative PH
domains, are depicted. Note that exon 4b
(isoform  b,  in  gray)  is  located  well
within the DAG kinase domain, while
isoforms c and d lack this domain. Grey
small  double  arrows  indicate  the
position of the primers used for specific
isoform  RT–PCR  analyses  (see
Methods). The figure is drawn to scale
except for the introns depicted with a
broken line.
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172retina  was  the  only  tissue  in  which  all  4  isoforms  were
expressed under the conditions tested. However, basal levels
of  most  isoforms  were  observed  in  most  tissues  after  a
saturating number of PCR cycles (data not shown).
CERKL  does  not  phosphorylate  ceramide  under  standard
conditions: Given the structural similarities of CERKL to the
reported  ceramide  kinases,  a  series  of  experiments  were
conducted to assess ceramide kinase activity. The protocol
from [10] with minor modifications was used for in vitro
ceramide kinase assays. We changed either of the following:
1) the source of the ceramides, namely a commercial mixture
of brain ceramides (Sigma) or lipid micelles prepared from
661W cells (mouse photoreceptor precursor cell line, kindly
provided by M.R. Al-Ubaidi) [11]; or 2) the source of the
enzymatic activity to be tested, namely protein lysates from
transiently  transfected  HEK293T  and  COS-7  cells
overexpressing  each  CERKL  isoform,  or  affinity-purified
recombinant GST-CERKL variants (after expression in E. coli
cells and only used in assays in vitro). No kinase activity was
detected for any isoform at any combination of the lipid and
protein lysate sources (Figure 3A). Additionally, lysates from
co-transfections  with  constructs  expressing  2  different
isoforms, or the 4 of them together, were assayed for kinase
activity. However, no significant difference with respect cells
transfected with the empty vector or single CERKL isoforms
could be detected (data not shown). We then attempted to
detect CERKL kinase activity in vivo using photoreceptor-
derived 661W cells. As 661W are neuronal, they transfect
poorly; therefore, we used CERKL-GFP fusion constructs to
enrich  by  FACS  the  population  of  transfected  cells.
Unfortunately, no differences were detected between cells
transfected with CERKL and the empty vector (Figure 3B).
The absence of kinase activity prompted us to test the
ability of CERKL isoforms to bind sphingolipids by protein-
lipid overlay. As PH domains have been reported to have an
affinity  for  phosphoinositides,  these  substrates  were  also
Figure 2. RT–PCR analysis of specific CERKL isoforms in several
human  tissues.  For  each  tissue,  lane  1  shows  amplification  of
isoforms  a  (fast  migrating  band)  and  b  (slow  migrating  band),
whereas lanes 2 and 3 show the amplified product of isoform c and
d, respectively. In the second gel, “f” represents fetal tissue. Marker
band sizes are indicated in base pairs (bp). The additional faint bands
in lane number 1 correspond to heteroduplexes of the PCR products.
included. We used the CERKLa isoform (532 aa, containing
the complete DAG kinase domain) either as a pure preparation
of recombinant GST-CERKL fusion protein (in E.coli) or as
total  fresh  protein  lysate  from  HEK293T  cultured  cells
transiently  transfected  with  the  CERKLa  HA-tagged
construct. Again, no positive binding signals were produced
(data not shown).
Subcellular CERKL localization is highly dynamic: Ceramide
and  other  sphingoid  lipids  are  highly  dynamic  membrane
components. Proteins involved in sphingolipid metabolism
appear  to  be  specifically  localized  in  subcellular
compartments of the secretory pathway, from the ER-Golgi
network to the plasma membrane. In this context, we aimed
to  determine  CERKL  subcellular  localization  by  transient
expression of each alternative splicing variant in cultured
COS-7 cells, as the 4 isoforms display a specific domain
architecture, which might account for slight differences in
Figure 3. CERKL kinase activity assays. A: The autoradiography of
one out of many thin layer chromatographies (TLC) from in vitro
assays is shown. Lipid micelles and heat-inactivated cell lysates from
661W (murine photoreceptor-derived cell line) cells were used as
substrates, whereas protein lysates from COS-7 cells transfected with
either empty vector (pcDNA), CERKL isoform a (532 aa), CERKL
isoform b (558 aa) or ceramide kinase CERK (positive control)
expressing constructs were the source of the enzymatic activity. B:
Autoradiography of a TLC from in vivo assays is shown. Cultured
661W cells were transfected with either pGFP (empty vector), or
CERKLa-GFP, CERKLb-GFP, or CERK-GFP (positive control),
selected by FACS and grown in a medium supplemented with 32P-
orthophosphate  (see  Material  and  Methods  for  details  on  the
protocols). C1P represents Ceramide-1-phosphate. The images are
representative of many different assays, with several experimental
parameters, such as the type of cell line and the CERKL isoforms
overexpressed, changed. The results of the assays were negative
under all the conditions tested.
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173Figure 4. CERKL-HA (isoform a, 532 amino acids) shows a dynamic subcellular localization in COS-7 transfected cells. A: Several cells per
field showed uniform distribution of CERKL in the cytosol and the nucleus, with clear exclusion from the nucleoli. B: A similar pattern but
with strong accumulation in the nucleoli (nuclei, counter-stained with DAPI, appear in blue). C and D: In most cells, CERKL was absent from
the nucleus and instead accumulated in clusters, preferentially in the perinuclear region (A). These two patterns were cell-specific and could
be observed in the same field (D). E: CERKL localized to several membranous subcellular compartments, mainly ER and Golgi. The markers
used were calnexin for ER, GM130 for Golgi, EEA1 for endosomes and MitoTracker for mitochondria. F: R257X truncated CERKL localized
preferentially in the nuclei, although it was also detected in the ER. Arrows highlight the relevant CERKL localizations, as immunodetected
with an anti-HA monoclonal antibody. Scale bar corresponds to 10 μm. The same results were obtained for all the CERKL isoforms, irrespective
of the epitope used, HA or GFP (data not shown). Abbreviations: endoplasmic reticulum (ER), endosomes (End), mitochondria (Mit).
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174function or compartment localization. We used C-terminal
HA-tagged CERKL isoforms (CERKL-HA), as well as the
fusion  CERKL-GFP  constructs,  in  these  transient
transfections.
Interestingly, neither a unique localization pattern nor a
restricted subcellular localization could be ascribed to any
CERKL isoform, as all variants showed similar patterns that
appeared to be cell-specific. Two main protein localizations
emerged  consistently  in  all  preparations,  as  seen  for  the
isoform CERKLa (532 amino acids; Figure 4A–D). Most cells
showed CERKL in a strong perinuclear distribution, while the
nucleus  was  practically  devoid  of  signal  (Figure  4C,D).
Additionally, few cells in each field presented CERKL within
the  nucleus,  where  it  was  either  localized  to,  or  clearly
excluded from, the nucleoli (Figure 4A,B,D). No exclusive
colocalization  with  reference  markers  of  subcellular
compartments  was  observed,  as  CERKL  colocalized  both
with the ER (calnexin) and Golgi matrix (GM130) markers
(Figure 4E). To further assess association of CERKL with
other membranous compartments, we assayed colocalization
to  endosomes  (EEA1)  or  mitochondria  (labeled  by
MitoTracker staining). However, no precise colocalization
was observed (Figure 4E). Instead, the mutant RP truncated
protein CERKLa R257X (the localization of CERKLb 257X
was  identical;  data  not  shown)  showed  a  more  stable
localization  pattern  in  the  ER  and  nuclei  (Figure  4F),  in
agreement  with  other  reports  [12,13].  Similar  CERKL
subcellular localization results were obtained at 24 h or 48 h
post-transfection,  although  a  shift  toward  perinuclear
accumulation was clearly observed. The same pattern was
obtained when analyzing the localization of all 4 CERKL-
GFP  isoform  constructs  (data  not  shown).  Overall,  these
results point to a highly dynamic localization of CERKL,
which may relocate according to the stimuli acting upon a cell.
To  further  confirm  that  CERKL  was  localized  at  the
membranous organelles, we performed subcellular organelle
fractionation in a sucrose gradient. Cells transfected with the
wild-type CERKLa isoform were homogenized, and nuclei
and cellular debris were discarded. Membranes were pelleted
by centrifugation, resuspended in 1.5 M sucrose, and further
centrifuged in a 5-step sucrose gradient, ranging from 1.5 M
to 0.25 M. Fractions were collected from bottom to top, run
in  an  SDS–PAGE  and  immunodetected  against  HA  (for
CERKL  detection)  or  distinctive  organelle  markers.  The
results (Figure 5) clearly showed that CERKL distributed to
the same fractions where the Trans-Golgi (TGN38), Golgi
(GM130), and ER (PDI) markers localized, although CERKL
was more abundant in the Trans-Golgi and Golgi fractions.
CERKL  protects  cells  from  apoptosis  in  oxidative  stress
conditions: One of the working hypotheses to explain why
mutations  in  CERKL  cause  RP  is  based  on  its  cellular
protective  role  through  the  regulation  of  the  ceramide/
ceramide-1-phosphate ratio [14]. Photoreceptors are under
constant oxidative challenge. Environmental stress as well as
genetic mutations (e.g., on CERKL) would make them more
susceptible to damage, tilting the survival/death balance and
triggering apoptosis. To test whether CERKL has a protective
role,  we  assayed  the  effect  of  CERKL  overexpression  in
transiently transfected cells under normal or oxidative stress
conditions. As most neuronal cell lines, retina derived cells
are very poorly transfected, so we had to resort to transfections
on COS-7 and HeLa cell lines to obtain statistically significant
results.
COS-7 cells were transfected with each of the CERKL
isoforms as well as the mutant RP protein, and cell death was
assayed by propidium iodide staining after treatment with
200 μM H2O2 for 4 h. The results were compared to those
obtained with cells transfected with either empty vector or a
construct expressing the known ceramide kinase, CERK (this
construct was a gift from F. Bornancin). Dead cells were
stained with propidium iodide and quantified (as a percentage)
against  total  cell  number  (Figure  6A).  Expression  of  the
CERKL  or  CERK  constructs  caused  a  slight  increase  in
mortality in basal conditions. Under oxidative stress, there
was  a  3.4-fold  increase  in  mortality  in  the  empty-vector
transfected cells, whereas cells overexpressing any of the 4
CERKL  isoforms  maintained  a  similar  mortality  rate  (no
increase  in  mortality)  with  a  high  statistical  significance
(Mann–Whitney,  p<0.05;  Figure  6B).  Remarkably,  the
CERKL R257X (the RP mutant) failed to protect cells; the
mortality rate increased under oxidative stress (Figure 6B),
Figure  5.  CERKL  colocalizes  with  Trans-Golgi,  Golgi  and  ER
markers. HeLa cells transfected with CERKLa-HA were submitted
to subcellular fractionation by sucrose gradient. The strongest signal
of CERKLa coincides with the Trans-Golgi TGN38 marker, but it is
also localized in the same fractions as the Golgi GM130 marker and
extends to the ER PDI marker fractions. The multiple banded pattern
observed  in  the  TGN38  immunodetection  has  been  previously
reported  as  this  protein  undergoes  complex  post-translational
modification  events.  CERKLa-HA  was  immunodetected  with  a
monoclonal anti-HA antibody. The lanes are numbered according to
the sucrose fractions as collected from 1 (bottom, with higher sucrose
concentration)  to  10  (top,  lower  sucrose  concentration).
Abbreviations: total protein lysate (L); supernatant after pelleting the
membranes by centrifugation at 100,000x g (S).
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175although to a lesser level than the empty-vector cells (1.8 fold
increase  in  mortality;  statistical  significance,  p<0.05  in
comparison to either CERKL isoforms or the empty vector).
As propididum iodide staining was performed on coverslips,
the transfection efficiency of each construct was assessed by
western detection on protein lysates of replicate transfections.
Propidium iodide labels both apoptotic and necrotic cell
nuclei.  We  attempted  then  to  determine  whether  this
protective  effect  of  CERKL  overexpression  was  on
preventing  cells  from  entering  apoptosis.  Activation  of
caspases is a well established event in apoptosis, and detection
of caspase-cleaved substrates, such as PARP-1 (poly-ADP-
Figure 6. Cells overexpressing CERKL showed no mortality increase
in a comparison of normal and oxidative stress conditions. A: The
histogram shows the mortality (depicted as percentage) of pyknotic
nuclei of COS-7 cells. Cells were transfected with either the wild-
type CERKL isoforms (named CERKLa to CERKLd), the truncated
RP form (R257X), CERK or the empty vector (negative control) and
grown in either normal conditions (dotted bars) or treated for 4 h with
200 μM H2O2 (solid bars). There was no increase in mortality when
the cells were transfected with any of the wt CERKL isoforms. In
contrast, there was an increase in mortality in cells transfected with,
either the empty vector, a CERK (ceramide kinase) construct or the
R257X  CERKL  mutant.  Statistical  significance  is  shown  by  an
asterisk (Mann–Whitney test, p<0.05). B: The histogram shows the
mortality fold-increase of H2O2-treated versus untreated cells for
each construct. Statistically significant differences are shown by
asterisks (Mann–Whitney test, p<0.05). More than 500 cells were
counted for each construct and condition, in 3 independent replicates.
ribose-polymerase)-1,  is  one  of  the  most  widespread
hallmarks to quantify cell apoptosis [15,16]. PARP caspase-
dependent cleavage was immunodetected in HeLa cells that
were transiently transfected with either the empty vector or
the CERKLa isoform (532 amino acids, encompassing the
DAG kinase domain) in normal or under oxidative stress
conditions, and using several reagents and concentrations:
300  μM  and  400  μM  H2O2,  fetal  bovine  serum  (FBS)
deprivation and 0.3 mM sodium nitroprusside (SNP). The
analysis  was  performed  at  different  window  times  to
determine the best range of conditions for quantification of
any potential protective effect. CERKL did protect against
apoptosis induced by oxidative stress (Figure 7A) in cells
treated with 300 μM H2O2. This effect was dependent on the
degree of oxidative insult, as it was much more effective at
300 μM (no apoptosis increase), than at 400 μM H2O2 (no
significant protection). It was also dependent on the type of
inducer,  as  cells  overexpressing  CERKLa  did  not  behave
differently  from  empty-vector  transfected  cells  after  FBS
deprivation or SNP addition.
This protective effect was also dependent on time, and
presented  an  effective  window  frame.  It  was  already
detectable  at  12  h  (Figure  7B)  with  an  average  of  20%
protection  (statistical  significance  p<0.05,  Mann–Whitney
test).  In  addition,  this  effect  appeared  to  be  much  more
prominent at 24 h (Figure 7C), where the protection appeared
to  be  maximal,  around  50%  protection  (p<0.05,  Mann–
Whitney test). However, the effect was no longer observed at
48 h (data not shown), where PARP cleavage was high and
comparable between empty-vector and CERKLa transfected
cells.  The  expression  of  CERKLa  was  comparable  in  all
transfections (65%–68%), as assayed by western blot (data
not  shown),  thus  the  observed  differences  were  solely
attributable  to  the  overexpression  of  this  isoform.
Interestingly, this protective effect at 24 h-treatment was only
found  for  the  full-length  CERKLa  but  not  the  truncated
R257X mutant (neither in the a nor the b isoform constructs;
Figure  7D),  in  accordance  to  the  pathogenicity  of  this
mutation.
DISCUSSION
There is mounting evidence that most human genes show
alternatively spliced isoforms, many of them regulated by
tissue-specific  factors.  Indeed,  alteration  of  alternative
splicing is frequently linked to severe genetic diseases [17].
We report the characterization of 4 in-frame alternatively
spliced  isoforms  of  CERKL,  which  is  responsible  for  an
autosomal recessive form of retinitis pigmentosa (RP26). In
our case, the isoform multiplicity increased the complexity of
the functional analysis of a yet to be characterized lipid kinase.
For instance, comparison of isoforms CERKLa and CERKLb
revealed  an  additional  exon  (E4b),  which  introduces  26
additional  amino  acids  in-frame  within  the  DAG  kinase
catalytic domain and immediately upstream of the phosphate-
Molecular Vision 2009; 15:168-180 <http://www.molvis.org/molvis/v15/a16> © 2009 Molecular Vision
176Molecular Vision 2009; 15:168-180 <http://www.molvis.org/molvis/v15/a16> © 2009 Molecular Vision
177
Figure  7.  Overexpression  of  CERKL
protects  HeLa  cells  from  apoptosis
caused  by  oxidative  stress.  A:  The
western  blot  of  the  PARP  apoptosis-
dependent cleavage was obtained and
immunodetected  24  h  after  treatment
with  several  oxidative  reagents,  as
indicated. The PARP precursor protein
size is 116 kDa, whereas the proteolytic
product  after  caspase-3  cleavage  is
85  kDa.  Cells  were  transfected  with
either  the  CERKLa  (532aa,
encompassing  the  kinasic  domain)  or
the  empty  vector  pcDNA3.
Immunodetection of tubulin was used
for normalization. This is one image of
several  similar  replicates.  The
transfection efficiency was comparable
as  assessed  by  western
immunodetection (data not shown). B
and  C:  Quantification  of  the  PARP-
cleaved  peptide  with  respect  to  total
PARP  immunodetected  protein  (both
precursor plus peptide) in empty vector
(red bars) versus CERKLa transfected
cells  (solid  bars)  under  the  different
treatments.  Basal  apoptosis  in  empty
vector  untreated  cells  was  arbitrarily
considered  100%.  CERKL  protection
against apoptosis was clearly detected
after 12 h treatment with 300 μM H2O2
compared  with  the  empty-vector
transfected cells, whereas in the other
oxidative  conditions  this  protective
effect  was  not  significant  (B).  This
protective  effect  of  CERKL  against
apoptosis induced by 300 μM H2O2 was
much  more  pronounced  after  24  h
treatment (C). D: The histogram shows
the quantification of the PARP-cleaved
peptide  with  respect  to  total  PARP
immunodetected  protein  (both
precursor plus peptide) in empty vector-
transfected cells (red bars) versus cells
transfected with either CERKLa (solid
bars),  the  R257X  CERKLa  mutant
(white  bars)  or  the  R257X  CERKLb
mutant (blue bars). Cells were grown
under normal conditions or treated with
different concentrations of H2O2. Basal
apoptosis  in  empty  vector  untreated
cells was arbitrarily considered 100%.
The protective effect is clearly detected
for the full-length protein but not for the
truncated mutants. NT-untreated cells; 300-cells  treated  with  300  μM  H2O2;400-cells  treated  with  400  μM  H2O2 ; FBS-cells  grown  in
 medium deprived  of  fetal bovine serum;  SNP-cells  grown in medium  supplemented  with  0.3  mM  sodium  nitroprusside;  R257Xa-cells
 transfected  with the   construct bearing the  R257X  mutation  in  the  CERKLa  sequence  background;  R257Xb-cells  transfected with the 
construct bearing the  R257X  mutation in the CERKLb sequence background. At least 3 independent experiments were used  for replication. 
Statistical significance is indicated by an asterisk (Mann–Whitney test, p<0.05).donor binding site (GGDGS). The position of this exon in the
presumptive catalytic domain makes it a good candidate for
modulating  the  catalytic,  substrate-  or  partner-binding
abilities  of  the  protein,  as  has  been  postulated  for
alternatively-spliced  exons  within  encoded  functional
domains after an in silico genomic survey [18]. Interestingly,
the other two in-frame isoforms, CERKLc and CERKLd, lack
the exons encoding the DAG kinase (mainly encoded in exons
4  and  5)  domain,  which  may  severely  compromise  the
catalytic  activity  while  preserving  other  functions,  among
them substrate recognition. That exons 4b and 5 share a rare
splice donor site (GC) strongly suggests that the production
of these alternatively spliced isoforms is regulated. Genome-
wide analyses on the usage of splice sites showed that only
0.69% of exon/intron donor sites are GC [19], making it highly
improbable that 2 such sites flanking exons tandemly arrayed
occurred in the same gene unless there was some kind of
regulation  behind.  Given  that  GC-  splice  donor  sites  are
intrinsically weak, explaining why 60% of the GC-flanked
exons are alternatively processed [20], and that this site is
evolutionarily conserved, CERKL splicing is probably highly
regulated.
From sequence comparisons and phylogenetic analysis,
CERKL unambiguously clusters within the ceramide kinase
subfamily of lipid kinases [2]. However, at present, there is
no experimental evidence to support CERKL kinase activity
on ceramides. Therefore, it still stands as an orphan lipid
kinase, in agreement with other reports [12,13]. It may well
be that, although not yet identified for other lipid kinases, a
partner  is  required  for  substrate  recognition  or  catalysis.
Alternatively, the substrate may be a ceramide-derived lipid
undetectable under standard ceramide separation conditions.
In any case, the presence of 4 different isoforms, of which 2
are devoid of the kinase domain, suggests that CERKL is
involved in cellular roles other than lipid phosphorylation.
Remarkably, in contrast to other lipid enzyme genes that are
spread  throughout  all  the  eukaryotes,  CERKL  may  be
exclusive  to  the  vertebrate  lineage.  Highly  homologous
sequences can be found in chick and fish, but no evidence of
CERKL is found in the lancelet, the closest chordate ancestor
to the vertebrates, which instead shows an unambiguous hit to
CERK  (data  not  shown).  Further  support  to  its  vertebrate
confinement  comes  from  the  fact  that  other  invertebrate
genomes, such as Drosophila and C. elegans, are also devoid
of any CERKL homologs. In this evolutionary context, the
more complex vertebrate retina may have required genes with
novel  enzymatic  functions  to  protect  cells  against  stress,
adding  further  refinement  to  the  metabolism  of  bioactive
lipids as second messengers.
The versatile subcellular localization of CERKL in the
COS-7 and HEK293T cell lines is common to all isoforms.
This complex and highly dynamic pattern may reflect changes
in the intracellular sphingolipid pools, as it occurs with other
proteins in the ceramide metabolism [21–24]. CERKL has
been reported to contain one bona fide nuclear localization
signal (amino acids 102–106) [13], which would account for
its import into the nuclei. In our studies and for all wild-type
CERKL isoforms, nuclear localization is not a general event.
Thus, the evident retention of the truncated R257X protein
mutant  seemed  relevant  to  pathogenesis  [13,14].  Further
investigation is needed to determine how and why CERKL is
imported into the nuclei and the nucleoli as well as what is the
function of the protein in these organelles. Indeed, transient
nuclear  localization  of  CERKL  may  be  related  to  the
regulation  of  the  chromatin-associated  ceramide  and
sphingomyelin  pools,  in  accordance  with  the  intranuclear
distribution of other key enzymes of the ceramide metabolism,
as happens for SMase [25], ceramidase [26], and SPHK2
[27]. In addition, the consistent localization in the ER and
Golgi  compartments  is  compatible  with  the  membrane-
associated  roles—such  as  non-vesicular  trafficking—
reported for lipid kinases and other lipid-related proteins. It
has  been  claimed  that  compartmentalization  of  ceramide
function  requires  transfer  between  different  membranous
organelles [8,21,23], although ceramide kinase activity has
also been detected in the cytosol, where it is not associated
with  membranes  [10],  This  indicates,  overall,  that  these
enzymes translocate between different compartments. In this
scenario,  the  observed  variable  CERKL  intracellular
distribution is not so surprising, particularly when considering
that  similar  protein  localization  dynamics—which  shift
depending on the cellular state or stimuli—are now being
reported for other proteins involved in lipid metabolism [5,
24,28]. Under our conditions, the 4 isoforms showed a similar
localization pattern, irrespectively of the epitope used (HA or
GFP), suggesting that the functional differences among them
are not dependent on subcellular localization. Besides lipid
phosphorylation, CERKL isoforms may be involved in the
regulation of its own enzymatic activity, lipid trafficking and
storage, as well as in binding to distinct substrates or protein
partners. In this context, the multiplicity of isoforms in the
same tissue (or even in the same cell) and the fact that two of
the four isoforms lack the lipid kinase domain, gives support
to the rationale of multiplicity of functions.
RP  is  characterized  by  progressive  depletion  of
photoreceptor cells through apoptosis. Many different genetic
defects  converge  in  retinal  cell  malfunction  and  trigger
programmed cell death. The retina consists of several ordered
layers of differentiated neuronal cells that are under constant
oxidative stress conditions due to light exposure and a high
metabolic rate. Therefore, photoreceptor survival depends on
the action of anti-apoptotic mechanisms to prevent premature
death. Our data support that CERKL plays a crucial protective
role  as  its  overexpression  protects  cells  from  entering
apoptosis. This protective effect is dependent on time and the
severity of the insult suggesting that CERKL overexpression
is  effective  only  under  a  range  of  stress  conditions,  but
probably  not  after  massive  cell  damage.  Remarkably,  the
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178R257X protein causing RP cannot protect cells after sustained
injury. The weak protective effect observed at 4 h treatment
with H2O2 was no longer detectable after 24 h treatment. This
RP mutation lies within the CERKL exon 5, which is skipped
in the variants that do not contain the DAG kinase domain
(isoforms CERKLc and CERKLd). Thus, these two variants
probably are not compromised in the RP26 patients. In this
context, the physiologic relevance of each CERKL isoform
and their particular contribution to retinal disorders is yet to
be  determined.  Conceivably,  the  RP  pathology  could  be
caused by the absence of the longer isoforms or alternatively,
the toxicity of the 2 truncated proteins. Our results, and the
fact that most transcripts with premature STOP codons are
degraded  by  nonsense  mediated  decay,  support  the  first
scenario.
To our knowledge this is the first time CERKL has been
shown to be directly involved in protection against apoptosis.
Thus,  we  link  RP-causative  mutations  to  a  regulatory
mechanism for cell survival, which highlights the feasibility
of an RP-gene therapy approach based on protection factors
to prevent photoreceptor neurodegeneration and promote cell
survival.
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